Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF (IMPLANT4)
A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of Nolasiban to Increase On-going Pregnancy Rate Following Fresh Single Blastocyst Transfer Resulting From IVF
Sponsor: ObsEva SA
Listed as NCT03758885, this PHASE3 trial focuses on Infertility and remains completed. Sponsored by ObsEva SA, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ObsEva SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Bielefeld, Germany , Brussels, Belgium , Budapest, Hungary , Burnaby, Canada , Copenhagen, Denmark , Heidelberg, Germany , Herlev, Denmark and 23 more locations